1.Evaluation the effectiveness in treatment of multiple myeloma \r\n', u'patient with VAD (Vincristin - Adriamycin - Dexamethason) \r\n', u'
Hoa Thi Nhu Nguyen ; Lan Thi Ngoc Nguyen
Journal of Medical Research 2007;53(5):138-143
Background: Multiple myeloma is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance to plasma cell leukemia. Objective: To evaluate the effectiveness in treatment of multiple myeloma with VAD. Subjects and method: A study included 26 patients with multiple myeloma diagnosed according to Tubiana - 1993 criteria, who treated by VAD at Bach Mai Hospital, from January 1998 to December 2006. This was a retrospective combined to longitudinal follow-up examination study. Results: Response rate to treatment was 75%, complete response rate was 41.7%. Remission rate was 91.67%, complete remission rate was 66.7%. The parameters such as hemoglobin, speed of blood precipition in the first hour, globulin, and creatinine changed statistically significant after treatment. The average survival time of the patients was 30.13 \xb1 4.8 months. Survival rate of 1 year after diagnosis was 80%, at 3 years after diagnosis was 26.67% and more than 5 years after diagnosis was 6.67%. Conclusion: VAD had relatively good results in treatment of multiple myeloma.
Multiple Myeloma/ therapy
2.About the treatment of multiple myeloma.
Chinese Journal of Hematology 2007;28(10):649-650
3.Combination chemotherapy for the treatment of multiple myeloma.
Hyo Jin KIM ; Chang In SEO ; Keun Chil PARK ; Heung Tae KIM ; Dae Seog HEO ; Yung Hue BANG ; Seonyang PARK ; Byoung Kook KIM ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1992;24(4):577-585
No abstract available.
Drug Therapy, Combination*
;
Multiple Myeloma*
7.Full-cycle Health Management of Multiple Myeloma.
Jia-Yu DUAN ; Jian CUI ; Wen-Jiao TANG ; Zhong-Qing ZOU ; Li ZHANG
Acta Academiae Medicinae Sinicae 2022;44(4):673-677
Multiple myeloma is a hematologic tumor characterized by clonal proliferation of plasma cells.The development of novel agents and immunotherapy have substantially improved the prognosis of multiple myeloma,with an expectable median survival beyond ten years.Therefore,there is an urgent need to improve the management of this disease.Health management is effective in controlling chronic diseases and full-cycle management should be implemented from the early to the end stage of the disease.Implanting the full-cycle concept into the health management of multiple myeloma will guide and standardize the advances in this field.This review focuses on the full-cycle concept of multiple myeloma and the corresponding application of health management at each stage of the cycle.
Humans
;
Immunotherapy
;
Multiple Myeloma/therapy*
;
Prognosis
Result Analysis
Print
Save
E-mail